Corcept Therapeutics Inc.

CORT

Held by 4 specialist biotech funds

High Convergence

4 funds opened new positions. Next phase3 readout (Nab-paclitaxel 80 mg/m^2): Mar 2025. Short interest: 12.9% of float.

BiotechnologyCEO: Joseph K. BelanoffIPO: 2004Website ↗

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Catalysts

Phase 2NegativeQ4 2005MifepristoneAlzheimer's DiseaseNCT00105105

Primary: effects on cognitionEnrollment:Target 160Sites: 21RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2006MifepristoneMajor Depressive Disorder, Psychotic DisordersNCT00130676

Primary: The change in a measure of psychosis (screening and on Days 0, 7, 14, 28, 42, and 56)Enrollment:257/257Sites: 23RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2006MifepristoneMajor Depressive DisorderNCT00146523

Primary: The change in a measure of psychosis (screening and on Days 0, 7, 14, 28, 42, and 56)Enrollment:247/247Sites: 19RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2006MifepristoneDepressive Disorder, MajorNCT00208156

Primary: To evaluate the safety and tolerability of Corlux (mifepristone) for the treatment of recurrent psychotic symptoms with major depression with psychotic features (PMD) who previously participated in Corcept Therapeutics Protocol C-1073-07Enrollment:87/87Sites: 13NA, TREATMENT

Phase 3Q4 2006MifepristoneMajor Depressive Disorder, Psychotic DisordersNCT00128505

Phase 3NegativeQ1 2007mifepristoneMajor Depressive Disorder, Psychotic DisordersNCT00128479

Primary: The change in a measure of psychosis (screen, Days 0, 7, 14, 28, 42, 56)Enrollment:443/443Sites: 44RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q3 2007MifepristoneWeight-Gain PreventionNCT00455442

Primary: To determine the efficacy of mifepristone in the prevention of olanzapine-induced weight gain in healthy male volunteers.Enrollment:57/57Sites: 1RANDOMIZED, DOUBLE

Phase 3PositiveQ1 2011mifepristoneCushing's SyndromeNCT00569582

Primary: Improvement in Diabetes and/or Glucose Intolerance. (Baseline to Week 24)Enrollment:50/50Sites: 17NA, TREATMENT

Phase 3PositiveQ2 2012MifepristoneCushing's Disease, Cushing's SyndromeNCT01371565

Primary: Number of Participants With Adverse Events (6 months)Enrollment:4/4Sites: 5NA, TREATMENT

Phase 3PositiveQ3 2012mifepristoneCushing's SyndromeNCT00936741

Primary: Number of Participants With Adverse Events (Up to three years.)Enrollment:30/30Sites: 15NA, TREATMENT

Phase 3Q4 2016mifepristoneCushing's DiseaseNCT01925092

Primary: Adverse events (collected during the12 week study and 4 week follow-up period; up to 16 weeks total.)0Sites: 1NA, TREATMENT

Phase 2PositiveQ3 2018CORT125134Cushing's SyndromeNCT02804750

Primary: Percentage of Participants With One or More Adverse Events (Group 1: up to Week 16; Group 2: up to Week 20)Enrollment:35/35Sites: 25NON_RANDOMIZED, TREATMENT

Phase 2Q2 2020Relacorilant with nab-paclitaxelSolid TumorsNCT02762981

Primary: Number of Participants With Dose-limiting Toxicity (Up to completion of Cycle 1 (up to 28 days))Enrollment:85/85Sites: 4NA, TREATMENT

Phase 2NegativeQ2 2021MiricorilantNonalcoholic Steatohepatitis (NASH)NCT03823703

Primary: Relative Change From Baseline in Liver Fat Content Assessed by Magnetic Resonance Imaging-Proton Density Fat Fraction (Baseline and up to ~Day 95)Enrollment:12/12Sites: 15RANDOMIZED, TRIPLE, TREATMENT

Phase 2NegativeQ4 2021ExicorilantMetastatic Castration-Resistant Prostate CancerNCT03437941

Phase 2Q3 2022MiricorlilantAntipsychotic-induced Weight Gain (AIWG)NCT04524403

Phase 3ApprovedQ2 2024RelacorilantCushing SyndromeNCT03697109

Phase 3PositiveQ1 2025Nab-paclitaxel 80 mg/m^2Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal NeoplasmsNCT05257408

Phase 2Q3 2026Relacorilant 150 mg once daily (QD)Ovarian Cancer, Fallopian Tube Cancer, Peritoneal NeoplasmsNCT06906341

Phase 2Sep 15, 2026Mifepristone 1200 mg dailyTreatment-resistant PTSDNCT06689254

Phase 2Q3 2026Nenocorilant 200 mgNeoplasmsNCT07276373

Phase 2Q3 2026Miricorilant (Cohort A)Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH)NCT06108219

Phase 2Q4 2026Dazucorilant 300 mgAmyotrophic Lateral SclerosisNCT05407324

Phase 2Q4 2026relacorilantCushing SyndromeNCT03604198

Phase 2Q3 2027RelacorilantAdenocarcinoma, Carcinoma, Pancreatic DuctalNCT07259317

Phase 2Q4 2027EnzalutamideMetastatic Breast CancerNCT06099769

Recent News & Research

PubMed

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.

# ROSELLA Trial Summary for CORT Investors The ROSELLA phase 3 trial demonstrates that relacorilant (Corcept's selective glucocorticoid receptor antagonist) combined with nab-paclitaxel improves overall survival in platinum-resistant ovarian cancer patients, potentially establishing a new standard of care in a significant unmet need. This positive OS data—the primary endpoint—supports relacorilant's commercial viability beyond its established indication (adrenocorticotropic hormone-independent Cushing's syndrome) and validates the immunomodulatory mechanism in solid tumors. The result substantiates Corcept's pipeline expansion strategy and could enable label expansion into platinum-resistant ovarian cancer, opening a larger addressable market with meaningful clinical differentiation.

Apr 18, 2026

PubMed

Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study.

# GRACE Trial Summary for CORT Investors **Clinical Findings:** The GRACE trial demonstrates that relacorilant (CORT's lead candidate) met its primary endpoint, showing statistically significant efficacy in reducing cortisol levels in Cushing's syndrome patients during the randomized-withdrawal phase, with a favorable safety profile supporting differentiation from existing therapies like mifepristone. **Commercial Implications:** This Phase 3 data strengthens CORT's competitive position in the rare Cushing's syndrome market, potentially supporting FDA approval and providing clinical evidence for market adoption; however, investors should assess the magnitude of benefit versus Korlym (mifepristone) and the addressable patient population to evaluate peak sales potential and timing to commercialization. **Why It Matters:** Cushing's syndrome is a high-unmet-need, ultra-rare indication with limited treatment options

Apr 1, 2026

PubMed

Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.

# Investment Summary: Not Applicable to CORT **This research is not relevant to Corcept Therapeutics.** The study examines enzalutamide (an androgen receptor antagonist developed by Astellas/Medivation) in prostate cancer patients, which is outside CORT's therapeutic focus. CORT's pipeline centers on glucocorticoid receptor modulators for Cushing's syndrome and other endocrine/metabolic disorders, with no overlap in indication, mechanism, or competitive positioning with prostate cancer therapeutics. **Recommendation:** Flag and exclude from CORT-specific tracking.

Mar 27, 2026

PubMed

Integrating Tumor Biology and Host Factors in mCRPC: The Prognostic Value of 'Time to Castration Resistance', Systemic Inflammation, and Comorbidity Burden in Patients Treated with Enzalutamide.

# Investment Summary: Limited Direct Relevance to CORT This study examines prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) patients treated with enzalutamide—a competitive product space where Corcept has no marketed presence. The research identifies biomarkers (time to castration resistance, systemic inflammation, comorbidity burden) that could inform patient stratification and treatment outcomes, but does not evaluate glucocorticoid receptor antagonists or address any mechanism relevant to Corcept's pipeline. **Investor Implication:** This article has minimal direct impact on CORT's valuation or clinical strategy, as it focuses on an oncology indication outside Corcept's therapeutic focus (Cushing's syndrome, PCOS, depression). Investors should continue monitoring Corcept's own clinical programs rather than this external prostate cancer literature.

Mar 23, 2026

PubMed

Aryl hydrocarbon receptor is critical for both AR-dependent and AR-indifferent enzalutamide resistance in castration-resistant prostate cancer.

# Research Summary: AhR-Mediated Enzalutamide Resistance in CRPC **Summary:** This study identifies the aryl hydrocarbon receptor (AhR) as a critical driver of enzalutamide resistance in castration-resistant prostate cancer (CRPC), functioning through both androgen receptor (AR)-dependent and AR-independent mechanisms. The finding suggests that dual AhR/AR targeting could overcome a major therapeutic resistance pathway affecting a significant proportion of advanced prostate cancer patients. **Investment Implications:** While this research does not directly implicate Corcept's mifepristone (glucocorticoid receptor antagonist), it highlights an emerging resistance mechanism in CRPC that could create companion diagnostic or combination therapy opportunities. For CORT investors, this underscores the competitive complexity in oncology and may indirectly validate glucocorticoid signaling as a complementary

Mar 23, 2026

Corcept Therapeutics Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research